Shares of Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) have been given a consensus rating of “Buy” by the six research firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $27.33.
Several brokerages recently issued reports on SBPH. ValuEngine upgraded shares of Spring Bank Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $32.00 price target (up previously from $29.00) on shares of Spring Bank Pharmaceuticals in a research report on Wednesday, February 21st.
A number of large investors have recently bought and sold shares of the stock. Millennium Management LLC bought a new stake in Spring Bank Pharmaceuticals during the fourth quarter worth about $676,000. BVF Inc. IL boosted its stake in Spring Bank Pharmaceuticals by 26.2% during the fourth quarter. BVF Inc. IL now owns 823,474 shares of the company’s stock worth $11,076,000 after acquiring an additional 170,798 shares in the last quarter. AXA boosted its stake in Spring Bank Pharmaceuticals by 7.6% during the fourth quarter. AXA now owns 266,585 shares of the company’s stock worth $3,583,000 after acquiring an additional 18,859 shares in the last quarter. Virtu Financial LLC bought a new stake in Spring Bank Pharmaceuticals during the fourth quarter worth about $172,000. Finally, BlackRock Inc. boosted its stake in Spring Bank Pharmaceuticals by 14.8% during the fourth quarter. BlackRock Inc. now owns 32,961 shares of the company’s stock worth $443,000 after acquiring an additional 4,259 shares in the last quarter. 28.65% of the stock is currently owned by institutional investors and hedge funds.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last announced its quarterly earnings results on Tuesday, February 20th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.18. equities analysts anticipate that Spring Bank Pharmaceuticals will post -2.4 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Brokerages Set Spring Bank Pharmaceuticals Inc (SBPH) PT at $27.33” was first reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://dakotafinancialnews.com/2018/04/13/brokerages-set-spring-bank-pharmaceuticals-inc-sbph-pt-at-27-33.html.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.